The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling

Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells

(2013) Murielle Mimeault et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer

(2010) Kakoli Das et al.   ENDOCRINE-RELATED CANCER

Clinicopathological features and treatment strategy for triple-negative breast cancer

(2010) Yutaka Yamamoto et al.   International Journal of Clinical Oncology

Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia

(2010) Lionel Flamant et al.   Molecular Cancer

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Triple-negative breast cancer--current status and future directions

(2009) O. Gluz et al.   ANNALS OF ONCOLOGY

Effect of dutasteride on the expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in rat and human prostate tissue

(2009) Ja Hyeon Ku et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY